Research programme: neuropathic pain therapeutics - Medisyn Technologies
Latest Information Update: 15 Jul 2016
At a glance
- Originator Medisyn Technologies
- Developer MD Biosciences; Medisyn Technologies
- Mechanism of Action GABA B receptor agonists; GABA receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Neuropathic pain
Most Recent Events
- 15 Jul 2016 Investigation in Neuropathic pain in USA (unspecified route)